UNICHEM LABORATORIES Latest Share Price (UNICHEMLAB)
TODAY IN ONE LINE
UNICHEMLAB fell 2.8% on light volume, lagging Nifty's -1.6% move.
With a market cap of ₹3,698.06 Cr., it trades at a P/E of 12.13. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
UNICHEM LABORATORIES flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Healthy Operating MarginsOPM is structurally strong at 15.7%
- ●Reasonable ValuationTrading at a moderate P/E of 13.3x
- ●High Promoter HoldingPromoters hold 70.2% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.02x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 79.3% YoY
- ●Sales ContractionQuarterly sales dropped 42.1% YoY
- ●Poor Capital ReturnsLow ROE of 6.0%
Latest UNICHEM LABORATORIES News
What changed recently?
Recent events, corporate actions, and announcements.
UNICHEM LABORATORIES valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for UNICHEM LABORATORIES, framed against the sector median so the premium or discount is obvious at a glance.
UNICHEM LABORATORIES trades at a P/E of 12.13× and P/B of 1.36×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
UNICHEM LABORATORIES technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for UNICHEM LABORATORIES — derived from the latest tape, not yesterday's close.
UNICHEM LABORATORIES last traded at ₹530.9 with an intraday range of ₹526.1–₹568.95 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹530.90| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 643.57 | +112.67 | +21.22% |
| R3 | 600.72 | +69.82 | +13.15% |
| R2 | 584.83 | +53.93 | +10.16% |
| R1 | 557.87 | +26.97 | +5.08% |
| PIVOT | 541.98 | 11.08 | 2.09% |
| CURRENT | 530.90 | — | — |
| S1 | 515.02 | -15.88 | -2.99% |
| S2 | 499.13 | -31.77 | -5.98% |
| S3 | 472.17 | -58.73 | -11.06% |
| S4 | 429.32 | -101.58 | -19.13% |
UNICHEMLAB is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹537.55–₹548
Trading Below opening range, showing Bearishness
UNICHEM LABORATORIES financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for UNICHEM LABORATORIES — consolidated or standalone — with margins, YoY growth and key ratios inline.
UNICHEM LABORATORIES reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹3,698.06 Cr. and reported EPS of ₹0.79.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 2,111 | 2,202 ▲ 4.3% |
| Sales Growth YoY %Derived | 23.82% | 4.31% |
| Other Income | 35 | 63 ▲ 78.5% |
| Total Income | 2,146 | 2,265 ▲ 5.5% |
| 864 | 1,021 ▲ 18.2% | |
| Gross ProfitDerived | 1,247 | 1,181 ▼ 5.3% |
| Gross Margin %Derived | 59.09% | 53.65% |
| 982 | 997 ▲ 1.5% | |
| EBITDA (Operating Profit)Derived | 265 | 184 ▼ 30.5% |
| OPM %Derived | 12.55% | 8.36% |
| 146 | 359 ▲ 146.3% | |
| Profit Before Tax (PBT) | 155 | 292 ▲ 89.1% |
| 17 | 40 ▲ 131.6% | |
| Effective Tax %Derived | 11.04% | 13.52% |
| Profit/Loss from Discontinued Ops | — | — |
| Total Profit for Period | 138 | 253 ▲ 83.9% |
| Net Profit (Owner's PAT)Derived | 138 | 253 ▲ 83.9% |
| Net Profit Margin %Derived | 6.51% | 11.48% |
| PAT Growth YoY %Derived | 295.13% | 83.86% |
| Earnings Per Share (EPS ₹) | 19.53 | 35.91 ▲ 83.9% |
| Diluted Shares Outstanding (Cr) | 7 | 7 ▲ 0.0% |
| Share of Profit from Associates/JVs | — | — |
| Other Comprehensive Income (Net of Tax) | -7 | 12 ▲ 272.0% |
| Total Expenses (incl. D&A & Interest) | 1,992 | 1,973 ▼ 1.0% |
| Material Cost % of RevenueDerived | 42.08% | 34.92% |
| Employee Cost % of RevenueDerived | 19.05% | 18.01% |
| Other Cost % of RevenueDerived | 27.49% | 27.27% |
| Interest Coverage (x)Derived | 6.67x | 1.87x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 818 | 1,180 ▲ 44.2% | 1,211 ▲ 2.6% | 1,235 ▲ 2.0% | 1,270 ▲ 2.8% | 1,343 ▲ 5.8% | 1,705 ▲ 26.9% | 2,111 ▲ 23.8% | 2,202 ▲ 4.3% | |
| Sales Growth YoY %Derived | — | 44.19% | 2.59% | 2.02% | 2.81% | 5.76% | 26.94% | 23.82% | 4.31% | |
| Other Income | 61 | 98 ▲ 61.3% | 91 ▼ 7.2% | 50 ▼ 45.0% | 48 ▼ 5.3% | 39 ▼ 18.9% | 32 ▼ 18.0% | 35 ▲ 11.8% | 63 ▲ 78.5% | |
| Total Income | 879 | 1,278 ▲ 45.4% | 1,302 ▲ 1.8% | 1,285 ▼ 1.3% | 1,317 ▲ 2.5% | 1,382 ▲ 4.9% | 1,736 ▲ 25.7% | 2,146 ▲ 23.6% | 2,265 ▲ 5.5% | |
358 | 445 ▲ 24.1% | 387 ▼ 13.0% | 379 ▼ 1.9% | 416 ▲ 9.6% | 551 ▲ 32.5% | 665 ▲ 20.6% | 864 ▲ 29.9% | 1,021 ▲ 18.2% | ||
| Gross ProfitDerived | 460 | 735 ▲ 59.8% | 824 ▲ 12.0% | 856 ▲ 3.9% | 854 ▼ 0.2% | 792 ▼ 7.2% | 1,040 ▲ 31.3% | 1,247 ▲ 19.9% | 1,181 ▼ 5.3% | |
| Gross Margin %Derived | 56.23% | 62.32% | 68.06% | 69.28% | 67.25% | 58.98% | 61.02% | 59.09% | 53.65% | |
592 | 819 ▲ 38.3% | 875 ▲ 6.8% | 765 ▼ 12.6% | 781 ▲ 2.2% | 838 ▲ 7.2% | 940 ▲ 12.2% | 982 ▲ 4.5% | 997 ▲ 1.5% | ||
| EBITDA (Operating Profit)Derived | -132 | -83 ▲ 36.8% | -51 ▲ 39.1% | 91 ▲ 279.3% | 73 ▼ 20.1% | -46 ▼ 162.6% | 100 ▲ 320.1% | 265 ▲ 164.2% | 184 ▼ 30.5% | |
| OPM %Derived | -16.13% | -7.08% | -4.20% | 7.38% | 5.73% | -3.39% | 5.88% | 12.55% | 8.36% | |
59 | 75 ▲ 28.0% | 90 ▲ 19.5% | 89 ▼ 0.0% | 97 ▲ 8.7% | 92 ▼ 5.2% | 78 ▼ 15.1% | 146 ▲ 86.0% | 359 ▲ 146.3% | ||
| Profit Before Tax (PBT) | -130 | -60 ▲ 53.7% | -49 ▲ 18.3% | 52 ▲ 205.7% | 23 ▼ 55.6% | -176 ▼ 865.8% | -62 ▲ 65.0% | 155 ▲ 350.7% | 292 ▲ 89.1% | |
3 | -34 ▼ 1127.7% | 12 ▲ 134.9% | 17 ▲ 43.3% | -11 ▼ 164.7% | 26 ▲ 333.2% | 9 ▼ 65.9% | 17 ▲ 93.8% | 40 ▲ 131.6% | ||
| Effective Tax %Derived | -2.58% | 57.27% | -24.42% | 33.10% | -48.17% | -14.67% | -14.28% | 11.04% | 13.52% | |
| Profit/Loss from Discontinued Ops | 2,678 | 2 ▼ 99.9% | — ▼ 100.0% | — | — | — | — | — | — | |
| Total Profit for Period | 2,545 | -26 ▼ 101.0% | -60 ▼ 135.5% | 34 ▲ 157.0% | 33 ▼ 3.7% | -202 ▼ 711.7% | -70 ▲ 65.2% | 138 ▲ 295.1% | 253 ▲ 83.9% | |
| Net Profit (Owner's PAT)Derived | 2,545 | -26 ▼ 101.0% | -60 ▼ 135.5% | 34 ▲ 157.0% | 33 ▼ 3.7% | -202 ▼ 711.7% | -70 ▲ 65.2% | 138 ▲ 295.1% | 253 ▲ 83.9% | |
| Net Profit Margin %Derived | 310.96% | -2.17% | -4.97% | 2.78% | 2.60% | -15.06% | -4.13% | 6.51% | 11.48% | |
| PAT Growth YoY %Derived | — | -101.00% | -135.48% | 157.03% | -3.68% | -711.67% | 65.15% | 295.13% | 83.86% | |
| Earnings Per Share (EPS ₹) | 361.82 | -3.38 ▼ 100.9% | -8.55 ▼ 153.0% | 4.88 ▲ 157.1% | 4.70 ▼ 3.7% | -28.72 ▼ 711.1% | -10.01 ▲ 65.1% | 19.53 ▲ 295.1% | 35.91 ▲ 83.9% | |
| Diluted Shares Outstanding (Cr) | 7 | 7 ▲ 0.1% | 7 ▲ 0.0% | 7 ▲ 0.0% | 7 ▲ 0.0% | 7 ▲ 0.0% | 7 ▲ 0.0% | 7 ▲ 0.0% | 7 ▲ 0.0% | |
| Share of Profit from Associates/JVs | -0 | 0 ▲ 129.2% | 1 ▲ 1146.5% | -0 ▼ 142.1% | -1 ▼ 209.8% | — ▲ 100.0% | — | — | — | |
| Other Comprehensive Income (Net of Tax) | -5 | 2 ▲ 140.8% | 3 ▲ 63.5% | 16 ▲ 436.4% | 54 ▲ 227.9% | 46 ▼ 14.6% | -5 ▼ 111.9% | -7 ▼ 27.3% | 12 ▲ 272.0% | |
| Total Expenses (incl. D&A & Interest) | 1,009 | 1,338 ▲ 32.7% | 1,351 ▲ 0.9% | 1,234 ▼ 8.7% | 1,294 ▲ 4.9% | 1,558 ▲ 20.4% | 1,798 ▲ 15.4% | 1,992 ▲ 10.8% | 1,973 ▼ 1.0% | |
| Material Cost % of RevenueDerived | 47.38% | 40.42% | 34.81% | 37.81% | 35.91% | 39.63% | 43.57% | 42.08% | 34.92% | |
| Employee Cost % of RevenueDerived | 24.52% | 20.28% | 22.57% | 24.85% | 26.03% | 26.54% | 23.05% | 19.05% | 18.01% | |
| Other Cost % of RevenueDerived | 47.84% | 49.11% | 49.68% | 37.05% | 35.49% | 35.83% | 32.08% | 27.49% | 27.27% | |
| Interest Coverage (x)Derived | -22.79x | -20.06x | -16.88x | 1.32x | -3.01x | -9.18x | -0.57x | 6.67x | 1.87x |
UNICHEM LABORATORIES segment analysis : revenue and profit mix.
Disclosed business segments at UNICHEM LABORATORIES with their share of revenue and profit, switchable between consolidated and standalone reporting.
UNICHEM LABORATORIES discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for UNICHEM LABORATORIES.
Our AI distills the core fundamental drivers supporting UNICHEM LABORATORIES, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
UNICHEM LABORATORIES's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. The security token included in the request is invalid.
Flip Conditions.
Valuation risk. a P/E above 16 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
UNICHEM LABORATORIES peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — UNICHEM LABORATORIES is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
UNICHEM LABORATORIES chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for UNICHEM LABORATORIES — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
UNICHEM LABORATORIES delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for UNICHEM LABORATORIES over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in UNICHEM LABORATORIES stood at 26.6% of traded volume, against a 20-day average of 35.3%.
UNICHEM LABORATORIES announcements: results, concalls, ratings, M&A.
Filings UNICHEM LABORATORIES sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
UNICHEM LABORATORIES files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 101 documents below.
Updates
Unichem Laboratories Limited has informed the Exchange regarding USFDA Inspection At Goa Formulation Facility
Trading Window
Unichem Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)…
Action(s) taken or orders passed
Unichem Laboratories Limited has informed the Exchange about Action(s) taken or orders passed
Updates
Unichem Laboratories Limited has informed the Exchange regarding 'Extension Of The Exercise Period For The Options Granted And Vested Under Unichem…
Spurt in Volume
Significant increase in volume has been observed in Unichem Laboratories Limited. The Exchange, in order to ensure that investors have latest…
Investor decks & rating reports.
UNICHEM LABORATORIES dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue UNICHEM LABORATORIES has declared, sequenced by announce and record date.
UNICHEM LABORATORIES corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About UNICHEM LABORATORIES: business, sector, key facts.
What UNICHEM LABORATORIES does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
UNICHEM LABORATORIES operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: UNICHEMLAB, BSE: 506690.
Unichem Laboratories Limited is a global pharmaceutical company with a long history, established in 1944 and headquartered in Mumbai, India. Their core business revolves around the manufacturing and sale of a wide range of pharmaceutical products, catering to diverse therapeutic areas and customer needs.
A significant portion of Unichem's business involves the production and distribution of formulated pharmaceutical products. These formulations target various therapeutic areas, demonstrating a broad approach to market segments. Specifically, their product portfolio addresses conditions and diseases related to gastroenterology, cardiology, diabetes (diabetology), psychiatry, neurology, bacterial infections (anti-bacterial), other infections (anti-infective), and pain management. This diverse portfolio allows them to reach a wide range of patients and healthcare providers.
Beyond finished formulations, Unichem also plays a key role in the supply chain by manufacturing active pharmaceutical ingredients (APIs). APIs are the fundamental building blocks of many drugs, and Unichem's production of these components positions them as a crucial player in the pharmaceutical industry, not only supplying their own formulations but also potentially supplying other pharmaceutical companies.
Further expanding their services, Unichem offers contract manufacturing services. This means they produce pharmaceutical products on behalf of other companies, effectively acting as a manufacturing partner for clients who may lack their own manufacturing facilities or require additional production capacity. This service stream contributes to their overall revenue and strengthens their position in the industry.
In summary, Unichem Laboratories Limited is a vertically integrated pharmaceutical company. They manufacture and sell a diverse range of finished pharmaceutical products targeting a wide array of therapeutic areas, produce the essential active pharmaceutical ingredients for those products and for others, and provide contract manufacturing services to external clients. This integrated model allows them to control various aspects of the pharmaceutical supply chain, enhancing their competitiveness and overall profitability.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about UNICHEM LABORATORIES (UNICHEMLAB).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of UNICHEM LABORATORIES (UNICHEMLAB)?
The current share price of UNICHEM LABORATORIES (UNICHEMLAB) is ₹530.90. Today, the stock has declined by ₹15.30 (2.8%), trading in a range of ₹526.10 to ₹568.95. The stock opened at ₹548.00 with a trading volume of 1,64,167 shares.
02Is UNICHEM LABORATORIES stock a good investment for long-term?
UNICHEM LABORATORIES can be considered for long-term investment based on several factors. The company has a market capitalization of ₹3,698.06 Cr., P/E ratio of 12.13, ROE of 6.05%, and ROCE of 9.11%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of UNICHEM LABORATORIES stock?
The 52-week high price of UNICHEM LABORATORIES (UNICHEMLAB) is ₹687.20, while the 52-week low is ₹278.20. Currently trading at ₹530.90, the stock is 90.83% above its 52-week low and 22.74% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy UNICHEM LABORATORIES stock at the current price?
Whether to buy UNICHEM LABORATORIES stock at ₹530.90 depends on multiple factors. The stock is currently trading with a P/E ratio of 12.13 and P/B ratio of 1.36. Today's performance shows a loss of 2.8%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of UNICHEM LABORATORIES and when is the next dividend?
UNICHEM LABORATORIES offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹530.90, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of UNICHEM LABORATORIES?
UNICHEM LABORATORIES's key financial metrics include: P/E Ratio: 12.13, P/B Ratio: 1.36, ROE: 6.05%, ROCE: 9.11%, Dividend Yield: 0%, EPS: ₹0.79, Book Value: ₹385.97, and Debt-to-Equity: 0.02. The company's market cap stands at ₹3,698.06 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is UNICHEM LABORATORIES stock performing today in the market?
UNICHEM LABORATORIES stock opened at ₹548.00 and is currently trading at ₹530.90, showing a decline of ₹15.30 (2.8%). The intraday high is ₹568.95 and low is ₹526.10. The trading volume stands at 1,64,167 shares, indicating moderate market participation today.
08What is the P/E ratio of UNICHEM LABORATORIES and what does it indicate?
UNICHEM LABORATORIES has a Price-to-Earnings (P/E) ratio of 12.13, which means investors are willing to pay 12.13 for every ₹1 of earnings. With an EPS of ₹0.79, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about UNICHEM LABORATORIES (UNICHEMLAB) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.